Anti-idiotypic antibody as an oestrogen mimetic: removal of Fc fragment converts agonist to antagonist.
Previous studies indicated that the anti-idiotypic antibody (clone 1D5) caused an increase in uterine creatine kinase (CK) activity when administered in vivo to immature female rats, indicating that the antibody has oestrogenic-like activity. It was, therefore, of interest to investigate the structural requirements of clone 1D5 to act as an oestrogen mimetic in an in vitro model system. In the present study, the effect of clone 1D5 and its proteolytic fragments, F(ab')2, Fab' and Fc on CK activity was examined in cultured skeletal cells having functional oestrogen receptor (ER). Incubation of female-derived calvaria cells or epiphyseal cartilage cells with clone 1D5 (8.33 nM) or oestradiol (E2) (30 nM) for 24 h caused a significant increase in CK activity, indicating that clone 1D5 acted as an agonist. On the other hand, incubation of male-derived calvaria cells devoid of a functional ER with clone 1D5 or E2 did not have any effect on CK activity. Incubation of female-derived calvaria cells with clone 1D5 and E2 did not result in any further increase in CK activity, whereas dihydrotestosterone (DHT) did not alter the response to clone 1D5. The CK response to clone 1D5, in female-derived calvaria cells was time- and dose-dependent and could be inhibited in a dose-dependent manner by the oestrogen antagonist tamoxifen. In contrast, the proteolytic fragments of clone 1D5, the F(ab')2 dimer (12 nM) and the Fab' monomer (24 nM), and the Fc fragment (28 nM) did not have E2-like activity in these cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Sömjen
D
D
Endocrine Unit, Ichilov Hospital, Tel Aviv, Israel.
Amir-Zaltsman
Y
Y
Gayer
B
B
Mor
G
G
Jaccard
N
N
Weisman
Y
Y
Barnard
G
G
Kohen
F
F
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology*; D002478:Cells, Cultured; D003402:Creatine Kinase / Q000378:metabolism*; D013196:Dihydrotestosterone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000378:metabolism; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D007140:Immunoglobulin Fab Fragments / Q000378:metabolism; D007141:Immunoglobulin Fc Fragments / Q000378:metabolism*; D008297:Male; D051381:Rats; D011960:Receptors, Estrogen / Q000378:metabolism; D012886:Skull / Q000378:metabolism; D013268:Stimulation, Chemical; D013629:Tamoxifen / Q000494:pharmacology; D013997:Time Factors; D014599:Uterus / Q000201:enzymology* / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D004965:Estrogen Antagonists; D004967:Estrogens; D007140:Immunoglobulin Fab Fragments; D007141:Immunoglobulin Fc Fragments; D011960:Receptors, Estrogen; D013196:Dihydrotestosterone; D013629:Tamoxifen; D004958:Estradiol; D003402:Creatine Kinase